Authors: Landowski, TH Moscinski, L Burke, R Buyuksal, I Painter, JS Goldstein, S Dalton, WS

Citation: Th. Landowski et al., CD95 antigen mutations in hematopoietic malignancies, LEUK LYMPH, 42(5), 2001, pp. 835

Authors: Shain, KH Landowski, TH Dalton, WS

Citation: Kh. Shain et al., The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance, CURR OPIN O, 12(6), 2000, pp. 557-563

Authors: Shain, KH Landowski, TH Buyuksal, I Cantor, AB Dalton, WS

Citation: Kh. Shain et al., Clonal variability in CD95 expression is the major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line, LEUKEMIA, 14(5), 2000, pp. 830-840

Authors: Catlett-Falcone, R Landowski, TH Oshiro, MM Turkson, J Levitzki, A Savino, R Ciliberto, G Moscinski, L Fernandez-Luna, JL Nunez, G Dalton, WS Jove, R

Citation: R. Catlett-falcone et al., Constitutive activation of Stat3 signaling confers resistance to apoptosisin human U266 myeloma cells, IMMUNITY, 10(1), 1999, pp. 105-115

Authors: Landowski, TH Shain, KH Oshiro, MM Buyuksal, I Painter, JS Dalton, WS

Citation: Th. Landowski et al., Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation, BLOOD, 94(1), 1999, pp. 265-274

Authors: Lamy, T Liu, JH Landowski, TH Dalton, WS Loughran, TP

Citation: T. Lamy et al., Dysregulation of CD95/CD95 ligand apoptotic pathway in CD3(+) large granular lymphocyte leukemia, BLOOD, 92(12), 1998, pp. 4771-4777